ORAGENICS, INC. Deferred Revenue
ORAGENICS, INC. (OGEN) had Deferred Revenue of $23.67 thousand as of 2013-03-31, per its 10-Q filed 2013-05-15.
Discontinued › Balance Sheet › Liabilities
us-gaap:DeferredRevenue · last filed 2013-05-15
- 2013-03-31: Deferred Revenue $23.67K.
- 2012-12-31: Deferred Revenue $27.81K.
| Period end | Deferred Revenue |
|---|---|
| 2013-03-31 | $23.67K 10-Q · filed 2013-05-15 |
| 2012-12-31 | $27.81K 10-Q · filed 2013-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |